Novartis is passing off the dry eye disease drop Xiidra to eye health specialist Bausch + Lomb in a $2.5 billion deal, another step in the company's overhaul as it focuses on five core areas. Bausch + ...

Xiidra is a prescription drug used to treat dry eye disease in people ages 17 years and older. Its recommended dosage is one drop in each eye twice daily, approximately 12 hours apart. The medication ...

Bausch + Lomb is expanding its ophthalmology portfolio and pipeline, paying Novartis $1.75 billion to acquire a commercialized drug for dry eye disease along with two experimental eye products. The ...

Please provide your email address to receive an email when new articles are posted on . Bausch + Lomb will acquire Xiidra and other assets from Novartis for a transaction of up to $2.5 billion. The ...

Xiidra (lifitegrast) does not have any known interactions with alcohol, other medications, or supplements. However, Xiidra has some health-related interactions. Xiidra is used in adults and children ...

Please provide your email address to receive an email when new articles are posted on . Two-thirds of respondents said patients had near or complete symptom resolution after Xiidra treatment. Mild or ...

Bausch + Lomb Corporation (NYSE:BLCO) has agreed to acquire 'front of eye' ophthalmology assets for $1.75 billion in upfront cash, plus additional milestone payments from Novartis AG (NYSE:NVS), ...

ZURICH (Reuters) - Swiss drugmaker Novartis has withdrawn an application for European approval of its Xiidra dry eye medicine after regulators concluded its effectiveness had not been demonstrated and ...

Novartis has entered into an agreement with Takeda Pharmaceutical Company Limited to acquire the assets associated with Xiidra (lifitegrast ophthalmic solution) 5% worldwide. Xiidra is the first and ...

(RTTNews) - Shares of Bausch + Lomb Corp. (BLCO) are gaining more than 8 percent on Friday morning after the company said that it has entered into a definitive agreement with Novartis to acquire ...

Bausch & Lomb announced an agreement with Novartis to acquire dry eye drug Xiidra (along with a few early-stage eye care products) for $1.75 billion in upfront cash and potential sales-based milestone ...

Medicare may cover Xiidra (lifitegrast ophthalmic solution) if you have a plan with prescription drug coverage, such as a Part D plan or a Medicare Advantage (Part C) plan. Xiidra is a brand-name drug ...